Back to Authors

Utz, David C.

Mayo Clinic

Mayo Clinic

Citations 44

The Treatment of Renal Cell Carcinoma with Solitary Metastasis
O’Dea, Michael J., Zincke, Horst, Utz, David C., Bernatz, Philip E.

Journal of Urology | June 29, 2017 | Volume: 120 | Issue: 5 | Pages: 540-542

10.1016/s0022-5347(17)57264-x Get It

Primary Carcinoma in Situ of the Ureter and Renal Pelvis
Khan, Ansar U., Farrow, George M., Zincke, Horst, Utz, David C., Greene, Laurence F.

Journal of Urology | June 29, 2017 | Volume: 121 | Issue: 5 | Pages: 681-683

10.1016/s0022-5347(17)56939-6 Get It

Treatment of Transitional Cell Carcinoma of the Bladder with Hematoporphyrin Derivative Phototherapy
Benson, Ralph C., Kinsey, James H., Cortese, Denis A., Farrow, George M., Utz, David C., Kinsey, J. H.

Journal of Urology | June 29, 2017 | Volume: 130 | Issue: 6 | Pages: 1090-1094

10.1016/s0022-5347(17)51699-7 Get It

Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment
Swanson, Gregory P. , Cupps, Roger E., Utz, David C., Ilstrup, D M, Zincke, Horst, Myers, Robert P., Swanson, Gregory P

The British Journal of Radiology | July 15, 2009 | Volume: 67 | Issue: 801 | Pages: 877-889

10.1259/0007-1285-67-801-877 Get It

Abstract Data on long-term follow-up for definitive therapy of prostate cancer are limited, especially for radiation therapy. Either surgery or radiation was used in 322 patients for treatment with curative intent, and follow-up was for a minimum of 15 years. Overall survival was nearly identical to that in an age-matched cohort. 5-, 10-, and 15-year recurrence-free survival rates were 77%, 63% and 53%, respectively. Grade and stage were significant prognostic factors for both recurrence and survival. More than 60% of the initial failures were local, and more than 25% of the failures occurred after 10 years. Radiation therapy was used in 137 patients with clinically staged disease. Radical retropubic prostatectomy and perineal prostatectomy were performed in 133 and 44 patients, respectively. In this group, pathological staging was used. Survival rates for surgically treated patients were better than those in the cohort population. In conclusion, overall long-term follow-up demonstrates that definitive treatment does not have an adverse effect on survival from prostate cancer. Local recurrence is a frequent cause of failure. Caution must be used in interpreting any prostate study with less than 10 years of follow-up, because 25% to 50% of the failures occur after that time.